L’Oréal Paris calls on Canadians to nominate extraordinary women for the 2020 Women of Worth Grant Award Program
L’Oréal Paris calls on Canadians to nominate extraordinary women for the 2020 Women of Worth Grant Award Program For the fourth consecutive year, $110,000 in charitable grants will be presented on International Women’s Day to 10 Canadian women who are making a beautiful difference in their communities and the world TORONTO, ON – L’Oréal Paris Canada today … Continue reading L’Oréal Paris calls on Canadians to nominate extraordinary women for the 2020 Women of Worth Grant Award Program
First New Retinoid Molecule Approved in Over 20 Years
First New Retinoid Molecule Approved in Over 20 Years Next-generation retinoid, AKLIEF® trifarotene cream 50 mcg/g is proven effective in both facial and truncal acne treatment THORNHILL, ON, Nov. 28, 2019 /CNW/ – Galderma, a global leader focused on meeting the world’s increasing skin health needs, announced today that Health Canada approved AKLIEF® trifarotene cream, 50 mcg/g … Continue reading First New Retinoid Molecule Approved in Over 20 Years
Joint declaration of the tripartite visit to Cameroon
Joint declaration of the tripartite visit to Cameroon JOINT FINAL DECLARATION OF THE TRIPARTITE VISIT OF THE CHAIRPERSON OF THE AU COMMISSION AND THE SECRETARIES GENERAL OF THE COMMONWEALTH AND THE OIF 28 November 2019 For immediate releaseThe Chairperson of the African Union Commission, Moussa Faki Mahamat, the Secretary-General of the International Organization of la Francophonie, Louise Mushikiwabo … Continue reading Joint declaration of the tripartite visit to Cameroon
Lumeca Health Expands Executive Team
Lumeca Health Expands Executive Team Appoints Leah Olson-Friesen Chief Operating Officer REGINA, Nov. 28, 2019 /CNW/ – Lumeca Health, one of Canada’s leading virtual healthcare platforms, is proud to announce the appointment of Leah Olson-Friesen to the role of Chief Operating Officer. With extensive management experience spanning over two decades, Olson-Friesen brings valuable leadership to Lumeca’s … Continue reading Lumeca Health Expands Executive Team
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD(1)
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD(1) BURLINGTON, ON, Nov. 27, 2019 /CNW/ – Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved OFEV® (nintedanib) as the first and only treatment indicated … Continue reading Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD(1)
